Bristol Gains Imaging Agent Pipeline Via DuPont Pharmaceuticals Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Bristol-Myers Squibb's acquisition of DuPont Pharmaceuticals includes an R&D pipeline of two imaging agents, one of which is pending at FDA, and a radiotherapeutic.